Heteroaryl Compounds with Cyclic Bridging Unit for Parasitic Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiparasitic agents for treating helminth infections in animals face challenges such as evolutionary resistance, limited spectrum of activity, and the need for repeated treatments, necessitating the development of new medicaments that can effectively and conveniently treat a wide range of parasitic helminth infections over a long period.
Innovation Solution
Development of novel heteroaryl compounds with specific structural formulas that can be used as medicaments for animals, including those with halogen, alkyl, alkoxy, or phenyl substitutions, which are effective against nematode, cestode, and trematode infections, and can be administered in pharmaceutical compositions or kits to treat parasitic infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known anthelmintic agents are used to treat helminth infections, then specific parasite types can be treated, but evolutionary resistance develops rendering the drugs obsolete
Solution Approach 1:
The patent modifies the chemical structure of known anthelmintic agents by replacing specific hydrogen atoms with halogen substituents (fluorine, chlorine, bromine, iodine) at defined positions in the molecular structure. This parameter change in the chemical composition creates novel compounds with potentially enhanced efficacy and resistance to evolutionary resistance while maintaining the core pharmacological activity against helminth parasites.
2Adaptability or versatility
If known anthelmintic agents with broader spectrum are used, then multiple parasite types can be treated, but the need for repeated treatments increases
Solution Approach 1:
The patent designs heteroaryl compounds with a cyclic bridging unit that can simultaneously target multiple types of helminth parasites (nematodes, cestodes, and trematodes) through a single administration. The molecular structure is engineered to interact with conserved biological targets across different parasite classes, enabling one compound to perform multiple anthelmintic functions and reduce the need for repeated or combination treatments.
3Adaptability or versatility
If novel heteroaryl compounds with specific structures are developed, then broad spectrum activity and resistance to existing agents can be achieved, but development complexity increases
Solution Approach 1:
The patent employs a modular molecular architecture where the heteroaryl compound consists of distinct functional segments: a heteroaryl group (Formula II or III), a cyclic bridging unit, and various substitutable positions (R1-R10). This segmentation allows systematic variation of individual components to optimize broad-spectrum activity while maintaining a manageable structural framework that simplifies synthesis and characterization compared to entirely de novo compound design.
Data Source
AI summary
This invention relates to certain heteroaryl compounds which may be used as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of parasitic infections such as helminth infections and the treatment of parasitosis caused by such infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to pharmaceutical compositions and kits comprising the compounds.